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Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people
worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of
all diagnosed cases of diabetes. The course of the T2DM is characterized by insulin
resistance and a progressive loss of β-cell mass. DM is associated with a number of
related complications, among which cardiovascular complications and atherosclerosis
are the main cause of morbidity and mortality in patients suffering from the disease.
DM is acknowledged as a low-grade chronic inflammatory state characterized by
the over-secretion of pro-inflammatory cytokines, including interleukin (IL)-1β, which
reinforce inflammatory signals thus contributing to the development of complications.
In this context, the pharmacological approaches to treat diabetes should not only
correct hyperglycaemia, but also attenuate inflammation and prevent the development
of metabolic and cardiovascular complications. Over the last years, novel biological
drugs have been developed to antagonize the pathophysiological actions of IL-1β. The
drugs currently used in clinical practice are anakinra, a recombinant form of the naturally
occurring IL-1 receptor antagonist, the soluble decoy receptor rilonacept and the
monoclonal antibodies canakinumab and gevokizumab. This review will summarize the
main experimental and clinical findings obtained with pharmacological IL-1β inhibitors in
the context of the cardiovascular complications of DM, and discuss the perspectives of
IL-1β inhibitors as novel therapeutic tools for treating these patients.
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DIABETES, INFLAMMATION AND CARDIOVASCULAR
COMPLICATIONS
Diabetes mellitus (DM) is a cardiometabolic disease that affects millions of people worldwide.
Accordingly, the World Health Organization (WHO) has acknowledged the disease as epidemic.
In adults, the prevalence of type 2 diabetes mellitus (T2DM) is markedly higher that that of type 1
diabetes mellitus (T1DM), since it accounts for at least 90% of all diagnosed cases of diabetes. The
rapid increase in the prevalence of T2DM has emerged as a major global health problem, mostly due
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to associated complications, medical costs and reduced life
expectancy. The course of the T2DM is characterized by insulin
resistance and a progressive loss of β-cell mass, together with the
onset of vascular complications including coronary heart disease,
stroke, peripheral vascular disease, and end stage renal disease,
making it a leading cause of death worldwide.
Diabetes mellitus is nowadays acknowledged as a low-grade
chronic inflammatory condition characterized by the over-
secretion of pro-inflammatory cytokines. A growing body of
evidence currently points at interleukin-1β (IL-1β), which is a
major player in a wide array of auto-inflammatory diseases, to
also act as key promoter of systemic and tissue inflammation
in DM (Dinarello et al., 2010; Sumpter et al., 2011). Indeed,
an enhanced expression of IL-1β in a high glucose milieu has
been described in human monocytes and macrophages (Shashkin
et al., 2006; Dasu et al., 2007), pancreatic islets (Maedler et al.,
2004), myocardium (Niu et al., 2014), and aortic endothelium
(Asakawa et al., 1997), while the upregulated IL-1β levels have
been described in the heart and the retina and retinal vessels from
diabetic rats, among other (Ares-Carrasco et al., 2009; Liu et al.,
2012).
Many pieces of evidence, including studies in humans, suggest
that IL-1β plays a role in insulin resistance, both in clinically
overt T2DM and pre-diabetic states (van Asseldonk et al.,
2011). Such conditions are characterized by an over-production
of adipocytokines, including IL-1β, that are locally associated
to the inflammation of the adipose tissue. Importantly, these
adipokines can also be released to the circulation and impact
on distant organs, including the heart or the vessels. In fact,
increased systemic and vascular inflammation are considered key
mechanisms underlying diabetic vasculopathy (Sowers, 2013). In
this context, a key role of pro-inflammatory cytokines, such as
IL-1β, in the development of cardiovascular complications of
DM is being considered (Raines and Ferri, 2005; Goldberg, 2009;
Sprague and Khalil, 2009; Frostegård, 2013; Krishnan et al., 2014).
Based on the above described autoinflammatory features
of DM, the pharmacological approaches to treat diabetes
should not only correct hyperglycaemia, but also target chronic
inflammation in order to prevent the development of metabolic
and cardiovascular complications. In this context, blocking IL-1β
arises as a challenging therapeutic option to treat the progression
of the disease and its complications.
IL-1β AND THE INFLAMMASOME
Interleukins are regulatory proteins with ability to accelerate or
inhibit inflammatory processes, as well as other tissue responses.
IL-1 belongs to the group of pro-inflammatory interleukins
together with IL-2, IL-6, IL-7, IL-8, IL-15, IL-17, and IL-18.
IL-1 may counterregulate anti-inflammatory cytokines such
as IL-4, IL-10, IL-11, or other cytokines, such as IL-12 and
IL-13 (Fisman et al., 2008). The IL-1 superfamily of cytokines
comprises IL-1α, IL-1β, the endogenous regulator of IL-1 activity
[a competitive IL-1 receptor antagonist (IL-1Ra)], IL-18, and
the newly discovered IL-33, among other. The IL-1 superfamily
is closely linked to both innate inflammation and immune
responses. IL-1α is constitutively expressed in most cells of
healthy subjects, although a role for this cytokine in disease is
being validated in the context of sterile inflammation (Dinarello
et al., 2012). In contrast, the expression of IL-1β is very limited
in health, but it is markedly enhanced in blood monocytes,
tissue macrophages and dendritic cells after stimuli like microbial
products and other cytokines, such as tumor necrosis factor
(TNF)α, IL-18, IL-1α, or IL-1β itself, as an autoinflammatory
mechanism (Dinarello et al., 2012).
Interleukin-1β is produced as a precursor peptide (pro-IL-1β),
which is N-terminal cleaved by caspase-1 or by the IL-1
converting enzyme (ICE) to form the active mature molecule.
Caspase-1, an intracellular cysteine protease, needs firstly to
be processed following the oligomerization of a complex
of intracellular proteins termed the inflammasome. A key
component of the inflammasome, NLRP3, plays a critical role
in the secretion of IL-1β and in pyroptosis, which is an
inherently inflammatory caspase 1-dependent mechanism of
cell death triggered by various pathological stimuli, such as
acute myocardial infarction (AMI) (Bergsbaken et al., 2009).
Remarkably, a human autosomal mutation in NLRP3 results
in enhanced caspase-1 activity and greater secretion of IL-1β
(Franchi et al., 2009).
Interleukin-1β triggers intracellular signaling cascades
through the activation of the interleukin-1 receptor, type I
(IL-1R1), which also binds IL-1α. IL-1R1 is characterized by
extracellular immunoglobulin-like domains and an intracellular
Toll/interleukin-1R (TIR) domain, and it requires heterodimer
formation with interleukin-1 receptor accessory protein
(IL-1RAcP) to exert intracellular signaling (Palomo et al., 2015).
IL-1R1 is expressed in all cells and its activation triggers multiple
and sequential phosphorylation events that result in nuclear
translocation of transcription factors. IL-1 activates JAK protein
kinases that phosphorylate serine and threonine residues, which
are the targets of the mitogen-activated protein kinase (MAPK)
family. MAPKs then stimulate the translocation of nuclear
factor (NF)-κB to the nucleus via the IRAK-TRAF6 pathway,
and enhance nuclear binding of c-jun and c-fos, for activator
protein (AP)-1 activation. Both NF-κB and AP-1 sites are
present in the promoter regions of many inflammation-related
IL-1-inducible genes that encode for diverse cytokines, adhesion
molecules, chemokines or pro-inflammatory enzymes, among
other (Palomo et al., 2015).
PHARMACOLOGICAL BLOCKADE OF
IL-1β
In view of the growing pathophysiological relevance of IL-1β
in a wide variety of diseases, novel biological drugs have been
developed over the last years to antagonize the actions of the
cytokine. The drugs targeting IL-1β that are currently approved
for clinical use are anakinra, rilonacept, and canakinumab, while
gevokizumab has received orphan drug designation. A brief
description of these drugs follows below.
Anakinra is a short-acting recombinant non-glycosylated
form of the naturally occurring IL-1Ra, which blocks the activity
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of both IL-1α and IL-1β. Anakinra was first approved for the
treatment of rheumatoid arthritis on a daily basis in 2001
(Dinarello et al., 2012). However, its clinical indications have
been extended so far to other diseases such as the cryopyrin-
associated periodic syndromes (CAPS), a group of rare inherited
auto-inflammatory diseases associated to pathogenic variants in
the IL-1-regulating genes NLRP3 and ILRN (Jesus and Goldbach-
Mansky, 2014). Anakinra nowadays occupies a relevant position
in IL-1 therapeutics as a result, of its excellent safety record even
in long-term treatments, among other (Kullenberg et al., 2016).
The development of soluble decoy receptors was later
introduced as a strategy to achieve IL-1 binding and
neutralization. Rilonacept is a long-acting dimeric fusion
protein that complexes the extracellular residues of the two
IL1 receptor subunits, IL-1R1 and IL-1RAcP, to the Fc portion
of IgG1. Rilonacept was approved in 2008 by the FDA for the
treatment of CAPS. Like anakinra, rilonacept binds both IL-1α
and IL-1β.
More recently, monoclonal antibodies that specifically target
IL-1β have been developed. Canakinumab is a human IgG1k
monoclonal antibody that binds and neutralizes soluble IL-1β,
with no cross-reactivity with other interleukins, including
IL-1α. Like rilonacept, canakinumab was approved for treating
CAPS, other rare periodic fever syndromes, and juvenile
arthritis (Dinarello et al., 2012). A second humanized IgG2
monoclonal antibody, gevokizumab, which also strongly binds
IL-1β has been designed as orphan drug by the Food and
Drug Administration (FDA) and the European Medicine
Agency (EMA) for treating a series of rare conditions,
including pyoderma gangrenosum, Schnitzler syndrome, chronic
non-infectious uveitis or congenital hyperinsulinism. Another
humanized IL-1 neutralizing antibody LY2189102 (Eli-Lilly and
Company) is currently under study (Sloan-Lancaster et al., 2013).
Furthermore, a novel approach to block IL-1β has been
developed by means of active vaccination against endogenous
pro-inflammatory proteins. The vaccine hIL1bQb consists of full-
length recombinant IL-1β coupled to virus-like particles, and it
has been shown to produce endogenous anti-IL-1β antibodies
in pre-clinical models. The vaccine is currently starting to being
tested in patients (Cavelti-Weder et al., 2016).
Beyond their yet approved indications, these drugs are
being currently used in both pre-clinical research and clinical
trials to assess their applicability to other conditions in which
IL-1β may play a key pathophysiological role. In the next
sections, the main pre-clinical findings on the modulation of
cardiovascular dysfunction by IL-1β pharmacological blockers
will be summarized. Moreover, the clinical trials assessing the
cardiovascular impact of IL-1β inhibition in the context of DM
will be reviewed.
IL-1β BLOCKADE AND EXPERIMENTAL
DIABETIC VASCULOPATHY
Endothelial Dysfunction
Endothelial dysfunction is a crucial and early manifestation
of vascular diseases. It is characterized by the impairment
of the relaxations induced by nitric oxide (NO) and other
vasodilator compounds (like prostacyclin or the endothelium
hyperpolarizing factor), while the endothelial vasoconstrictor
factors are increased (Félétou and Vanhoutte, 2006).
A pro-oxidant and pro-inflammatory vascular environment
is another characteristic of endothelial dysfunction (Félétou and
Vanhoutte, 2006). Endothelial dysfunction is linked to the early
development of DM in both humans and experimental animal
models, and associated to reactive oxygen species (ROS) over-
production (Durante et al., 1988; Calver et al., 1992; Johnstone
et al., 1993; Angulo et al., 1998; Rodríguez-Mañas et al., 2003a,b).
There is also increasing evidence suggesting that the
development of an inflammatory environment in the vasculature
by pro-inflammatory cytokines is followed by an impairment
of endothelial function. Thus, acute systemic inflammation in
response to Salmonella typhi vaccine produces a temporary but
profound dysfunction of human arterial endothelium in both
resistance and conduit vessels, which is related to cytokine
production (Hingorani et al., 2000; Kharbanda et al., 2002).
Moreover, it is now well established, either in experimental
models and humans, that pro-inflammatory cytokines impair
vascular reactivity in different vascular beds, including resistance
vessels (Vila and Salaices, 2005).
Although the IL-1 pathway is considered at present a critical
player in the pathophysiology of both T1DM and T2DM
(Donath and Shoelson, 2011; Herder et al., 2015), the evidence
on the impact of IL-1β on vascular function is still limited.
In isolated resistance microvessels from non-diabetic animals,
IL-1β produces endothelial dysfunction after different exposure
times to the cytokine (Wimalasundera et al., 2003; Jiménez-
Altayó et al., 2006; Vallejo et al., 2014). Interestingly, the
impairment of endothelial function may occur even after a
rather short incubation with IL-1β (30 to 120 min), when
the possible pro-inflammatory responses triggered by the
cytokine are not fully developed, as indicated by the lack
of involvement of inducible pro-inflammatory enzymes that
require de novo synthesis (Vallejo et al., 2014). This early
endothelial dysfunction evoked by IL-1β is rather due to the
IL-1 receptor-mediated activation of NADPH oxidase, which
enhances superoxide anion (O•−2 ) production (Vallejo et al.,
2014). Interestingly, NADPH oxidase over-activation has been
linked to excess ROS generation and the development of
atherosclerosis in the context of diabetic vasculopathy (Olukman
et al., 2010; Gray et al., 2013). The pharmacological blockade
of IL-1 receptors by anakinra permits to attenuate both
NADPH activation and endothelial dysfunction induced by
IL-1β in microvessels from non-diabetic animals (Vallejo et al.,
2014).
Interestingly, the intraperitoneal administration of anakinra
can also partially recover the endothelial dysfunction observed
in experimental diabetes after 15 days of diabetes induction
(Vallejo et al., 2014). The animals receiving the drug exhibited
a clear improvement of endothelium-dependent relaxations
that was paralleled by the normalization of NADPH oxidase
activity in the vascular wall (Vallejo et al., 2014). Intriguingly,
the circulating levels of IL-1β were not found to be enhanced
(Vallejo et al., 2014), as previously reported by others in
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experimental models (Yazar et al., 2011) or in diabetic patients
(Mooradian et al., 1991; Pereira et al., 2014). The local over-
expression of IL-1β in the vascular wall may be responsible for
a paracrine inflammatory response, similarly to that described
in vitreous samples from patients with proliferative diabetic
retinopathy (Patel et al., 2008). In addition, other long-lasting
pro-inflammatory mechanisms induced by IL-1β can be involved
in the endothelial dysfunction associated to experimental
diabetes, since improved endothelium-dependent relaxation was
observed after the pharmacological blockade of cyclooxygenase
or the inducible form of nitric oxide synthase (iNOS) (Vallejo
et al., 2014).
Vascular Inflammation and
Atherosclerosis
Chronic vascular inflammation is at the basis of atherosclerosis,
which in turn accounts for life-threatening complications of DM
such as AMI or stroke. The pro-inflammatory cytokines IL-1β
and IL-1α are widely expressed in human and experimental
atherosclerotic lesions (Frostegård et al., 1999; Liu et al.,
2014) and a large body of preclinical data reveals that
IL-1β plays a major role in the progression and rupture
of atherosclerotic plaques (Chi et al., 2004; Isoda et al.,
2004; Merhi-Soussi et al., 2005; Chamberlain et al., 2006;
Frostegård, 2013; Singla et al., 2016). Thus, a rationale
is set for the use of pharmacological IL-1β blockers as
tools to delay the onset and progression of atherosclerotic
lesions.
One of the earliest steps of atherosclerosis is the recruitment
of leukocytes by endothelial cells via the expression of adhesion
molecules such as ICAM-1 and VCAM-1. The saturated fatty
acid palmitate, which is linked to a higher risk of type 2
diabetes and cardiovascular disease, promotes the release of IL-
1β by monocytes and their adhesion to human endothelial cells
(Shikama et al., 2015). This effect can be blocked by anakinra,
which prevents the induction of adhesion molecules elicited by
IL-1β (Shikama et al., 2015).
An imbalanced trafficking and distribution of intracellular
cholesterol has been associated with defective signaling and
vascular cell dysfunction (Schreiber, 2002). In cultured vascular
smooth muscle cells, serum amyloid A, which is expressed in
atherosclerotic lesions, promotes cholesterol trafficking via the
release of IL-1β (Pessolano et al., 2012). This effect can be
inhibited by the recombinant form of IL-1Ra (Pessolano et al.,
2012), and presumably, by IL-1β blocking drugs, although this
point still needs to be addressed.
Moreover, the dysruption of the endoplasmic reticulum
(ER) homeostasis by high glucose or other factors has been
identified over the last years as an important mechanism that
underlies many complications of type 2 such as endothelial
dysfunction, vascular inflammation and atherosclerosis (Lenna
et al., 2014). Chronic ER stress leads to the so-called unfolded
protein response (UPR), which ultimately seeks to restore ER
function but can also lead to cell death and apoptosis (Lenna
et al., 2014). In a murine model of type 2 diabetes, the
intraperitoneal injection of anakinra during 4 weeks diminished
ER stress and macrophage infiltration, and improved ischemia-
induced neovascularization and blood flow as compared with
untreated animals (Amin et al., 2012). These effects were
further accompanied by a normalization in the blood levels of
cholesterol and adiponectin without affecting glycemia (Amin
et al., 2012).
It is also worth noting that the pro-inflammatory signaling
elicited by IL-1β in human vascular cells can be exacerbated
by high glucose. In human endothelial cells, the expression of
adhesion molecules such as ICAM-1 and VCAM-1 induced by
IL-1β or TNF-α is augmented in the presence of extracellular high
glucose (Azcutia et al., 2010). Functionally, the synergy between
IL-1β and high glucose leads to an exaggerated leukocyte-
endothelial adhesion in vitro, together with enhanced rolling
flux and emigration of leukocytes in animal experimental models
in vivo (Azcutia et al., 2010). Similarly, in human vascular smooth
muscle cells IL-1β triggers the activation of pro-inflammatory
pathways such as the ERK 1/2- NF-κB- inducible nitric oxide
synthase (iNOS) axis (Lafuente et al., 2008). Such an effect
of IL-1β is exaggerated proportionally to the concentration of
extracellular glucose (Lafuente et al., 2008). As an explanation
for this synergy, it has recently been shown that IL-1β permits
the entry of extra glucose across the plasma membrane of
human vascular smooth muscle cells (Peiró et al., 2016). Part
of this excess intracellular glucose is then driven by the pentose
phosphate pathway to produce NADPH that in turn fuels the
pro-oxidant enzyme NADPH oxidase. The over-production of
ROS seems ultimately to be responsible for the exaggerated
NF-κB activation and iNOS induction triggered by IL-1β under
high glucose conditions (Peiró et al., 2016). By using anakinra,
not only the pro-inflammatory and pro-oxidant signaling elicited
by IL-1β in vascular cells was blunted but also, and importantly,
its exacerbation by extracellular high glucose (Peiró et al.,
2016).
Despite the promising pre-clinical data available to date
(Figure 1), the ability of anakinra or other IL-1β blocking
drugs to prevent or retard diabetes-associated experimental
atherosclerosis remains to be better established and requires
additional research with in vivo models. The scarce data available
on IL-1 blockade and atherosclerosis in patients suffering from
T2DM will be presented later in this review.
Accelerated Vascular Aging
Type 2 diabetes, together with obesity, has been shown to
accelerate aging processes and, particularly, vascular aging
(Minamino and Komuro, 2007; Barton, 2010). Indeed, besides
presenting endothelial dysfunction and a pro-inflammatory
status, animal models of obesity or diabetes exhibit core
hallmarks of vascular aging and cardiovascular pathologies,
such as arterial stiffness, calcification, and endothelial cell
senescence (Brodsky et al., 2004; Sloboda et al., 2012).
In humans, different reports have evidenced that patients
suffering from type 2 diabetes display a higher propensity
to calcified arteries, especially in the vasculature of lower
extremities and in the coronary artery (Chen and Moe, 2003;
Zhu et al., 2012), while they also exhibit enhanced arterial
stiffness (Laugesen et al., 2013). The presence of senescent
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FIGURE 1 | Mechanisms by which IL-1β may directly promote vascular dysfunction and their inhibition by the IL-1Ra recombinant analog anakinra. In vascular
smooth muscle cells (VSMC), IL-1β synergizes with extracellular high glucose (HG) to exacerbate pro-inflammatory signaling. iNOS, inducible nitric oxide synthase;
Glut1, glucose transporter 1; IL-1R, interleukin-1 receptor; NADPH ox., NADPH oxidase; PPP, pentose phosphate pathway; ROS, reactive oxygen species.
endothelial cells has been demonstrated in atherosclerotic
lesions from aortae and coronary arteries of rat models
of diabetes (Chen et al., 2002; Minamino et al., 2002).
Vascular senescence is associated to a series of morphological
and metabolic disturbances that result in dysfunctional cell
homeostasis (Erusalimsky, 2009) The senescence-associated
secretory phenotype is characterized by enhanced cytokine
secretion that in turn drives local inflammation and vascular
dysfunction (Erusalimsky, 2009). Overall, the occurrence of
vascular premature aging in patients suffering from obesity
and/or T2DM favors the development of vascular disease,
markedly enhances cardiovascular risk and worsens the life
expectancy of these patients. To date, there are few studies
available on the impact of IL-1β on accelerated vascular aging. It
is known, however, that it can promote both alkaline phosphatase
expression and mineralization in cultured vascular smooth
muscle cells, as two mechanisms favoring vascular calcification
(Lencel et al., 2011). We have also recently observed that
IL-1β can induce the accumulation of senescence-associated
β-galactosidase in cultured human endothelial cells, an effect
that can be dampened by anakinra (Peiró et al., unpublished
results).
IL-1β INHIBITION AND DIABETIC
CARDIOMYOPATHY
Role of IL-1β in the Heart Failure
Heart failure (HF) is a complex clinical syndrome characterized
by impaired cardiac function (left ventricular ejection fraction
less than 40%), and enhanced inflammation which is associated
with worsening outcomes in these patients. Although infection
with microorganisms is not involved in the development of
HF in most cases (sterile inflammation), inflammation has been
implicated in the pathogenesis of HF. In this regard, IL-1β
exerts crucial effects on most cell types involved in cardiac
repair and injury, and beneficial and detrimental effects of
IL-1β have been reported (Bujak and Frangogiannis, 2009). The
pro-inflammatory and pro-fibrotic responses after myocardial
injury serve to clear the wound and facilitate wound healing and
scar formation, and an excessive inhibition of the inflammatory
response can develop a defective scar (Frangogiannis et al., 2005).
Also, in myocardial ischemia-reperfusion (I/R) injury, IL1β and
IL1α pretreatment reduces ROS generation and a subsequent
increase in glucose-6-phosphate dehydrogenase activity, which
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provides cytoprotective effects against oxidation (Hedayat et al.,
2010). However, excessive upregulation or chronic stimulation of
IL1β and IL1α have been linked to deleterious responses.
IL-1β and Cardiac Inflammation
During an ischemic episode, myocardial contractile force
diminishes, Ca+2 homeostasis is altered, O2-derived ROS
are generated, NO is released, and local production of
cytokines, particularly TNF-α and IL-1β is increased.
IL-1β was described as an early upregulated cytokine in
cardiac inflammation that becomes chronically elevated
after impaired myocardial function and LV hypertrophy
following AMI (Toldo et al., 2014; Fang et al., 2015). These
cytokines enhance the expression of cyclooxygenase-2, and
phospholipase A2, as well as vascular adhesion molecules
and several chemokines. Interactions between chemokines
and cell adhesion molecules activate the innate and adaptive
immune system on endothelial cells of leukocytes. Then, an
immediate cytokine-mediated neutrophil and mononuclear cells
recruitment and extravasation in the infarcted myocardium
further damages heart muscle (Herskowitz et al., 1995). In
addition, IL-1β signaling, together with Toll-like receptors
activation (TLR), stimulate NF-κB to increase the expression
of more cytokines, chemokines, and adhesion molecules
(Figure 2). Remarkably, NF-κB and TLRs signaling upregulate
also pro-IL-1β (Fang et al., 2015). Finally, IL-1β is able to
activate spleen monocytopoiesis following AMI to stimulate
further monocyte production. Thus, excessive IL-1β signaling
and inflammation has been linked to increased incidence of
arrhythmia and other AMI-related pathologies (Fang et al.,
2015).
IL-1β, Cardiac Hypertrophy, and Contractile
Dysfunction
After a cardiac insult, IL-1β is also involved in the myocardial
hypertrophic growth response by direct gene expression
to compensate for environmental stresses (Figure 2). The
expression of IL-1β is increased in pressure and volume overload-
induced cardiac hypertrophy (Dai et al., 2004; Higashikuni et al.,
2013), and IL-1β induced growth of isolated cardiomyocytes
(McTiernan et al., 1997). Transgenic mice with constitutively
cardiac-specific overexpression of IL-1β produced myocyte
hypertrophy and HF (Palmer et al., 1995). This hypertrophic
response was NO-independent and lead to activation of
the fetal gene program by upregulation of atrial natriuretic
factor and β-myosin heavy chain. In addition, IL-1β, in
synergism with TNF-α, have demonstrated an exacerbation
of heart contractile dysfunction. IL-1β decreased myocardial
contractility by overexpressing iNOS in cardiomyocytes. Then,
NO was released to promote a cardiodepressant effect by
directly blocking the mitochondrial activity and reducing
energy depletion (Stein et al., 1996). This effect of IL-1β was
enforced by amelioration of calcium regulatory genes such
as sarcoplasmic reticulum Ca2+-ATPase, phospholamban, and
voltage dependent calcium channel, and subsequent decrease
of basal and stimulated contractility (Oddis and Finkel, 1995;
Tatsumi et al., 2000).
IL-1β, Cardiac Necrosis/Apoptosis, and Autophagy
The uncontrolled inflammation in the injured heart, as in AMI,
induces cellular apoptosis and progressive cardiac dysfunction.
The progression from cardiac injury to symptomatic HF
is mainly due to a loss of functional cardiac myocytes
through necrosis, autophagy/mitophagy, intrinsic and extrinsic
apoptosis (Gordon et al., 2011). Autophagy and mitophagy
have been recently characterized as essential cellular processes
in the heart, but whether these functions as pro-death
or pro-survival programs during disease conditions is still
not completely understood. The link between autophagy,
mitochondria, and inflammation in the heart has been established
(Oka et al., 2012). In particular, in diabetes, mitochondrial
DNA, a by-product of insufficient mitophagy, induced sterile
inflammation and subsequent cardiac dysfunction through the
TLR9 pathway, and increasing IL-1β, IL-6, and infiltration of
CD68+ macrophages.
Nevertheless, myocyte extrinsic apoptosis is the most
significant mechanism of cell loss and the end point of
pathological remodeling induced by cardiac injury, enhanced
autonomic activity, and cytokine secretion (Figure 2). In
AMI, the acute releasing of IL-1β and TNFα can regulate
the survival or apoptosis of myocytes in infarcted zone.
They also produce a negative inotropic effect as an adaptive
response to delimit the injury and decrease myocardial energy
demand (Schulz et al., 1995). In vitro, in cultured cardiac
myocytes, IL-1β induced programmed cell death through a
cGMP-independent NOS induction, and by generation of
ROS, activation of caspases, and alteration of the cellular
Bak/Bcl-xL ratio (Abbate et al., 2008). On the other hand, the
presence of necrosis has been demonstrated in most cardiac
injuries (Shinde and Frangogiannis, 2014). Necrotic cells
release danger signals, activating innate immune pathways
and triggering an intense inflammatory response. Stimulation
of TLR signaling and complement activation prompted
NF-κB and related upregulation of proinflammatory cytokines
(i.e., IL-1β, IL-1α, and TNFα) and chemokines (i.e., MCP-1 and
CCL2). Interestingly, some NF-κB target genes such as TNFα,
and p53 directly induced also intrinsic apoptosis (Shakhov et al.,
1990).
IL-1 and Cardiac Fibrosis
The adult mammalian myocardium contains abundant
fibroblasts entrapped within the interstitial and perivascular
extracellular matrix (ECM). After a massive sudden loss of
cardiomyocytes following AMI, the limited regenerative capacity
of the myocardium overcomes, resulting in the formation
of a collagen-based scar (Prabhu and Frangogiannis, 2016).
In the early stages of infarct healing, fibroblasts become
pro-inflammatory cells, activating the inflammasome and
producing cytokines, chemokines and proteases. NLRP3
inflammasome is predominantly upregulated in the cardiac
fibroblasts of the ischemic myocardium in animal models with
AMI (Fang et al., 2015). Then, pro-inflammatory cytokines,
such as Interleukin-1, delay myofibroblast transformation,
until the wound is cleared by infiltrated leukocytes from dead
cells and matrix debris. Suppression of the inflammatory
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FIGURE 2 | IL-1β activation in cardiac damage. After cardiac injury such as AMI or I/R, exacerbated IL-1β signaling can induce NFκB and AP-1 activation and
subsequent increase of pro-hypertrophic, contractile, inflammatory, apoptosis/necrosis, and fibrotic genes for autocrine and paracrine responses. These effects are
reinforced in the diabetic myocardium, and can be stimulated by TNFα and TLRs signaling. However, some drugs may specifically target IL-1β actions by NLRP3,
IL-1β, and IL-1R blockade. ECM, extra cellular matrix proteins.
response triggers activation of reparative cells. Thus, fibroblasts
migrate, proliferate, undergo myofibroblast transdifferentiation,
and deposit large amounts of ECM proteins to maintain the
structural integrity of the infarcted myocardium. In particular,
IL-1 signaling regulates reparative processes by modulating gene
expression of growth factors and ECM proteins (i.e., procollagen
α1-IV, α2-IV, and fibronectin) in fibroblasts and smooth muscle
cells, and by altering the Matrix Metalloproteinase (MMP)/Tissue
Inhibitor of Metalloproteinases (TIMP) balance (Prabhu and
Frangogiannis, 2016) (Figure 2). IL-1 increased MMP-1, MMP-3,
MMP-7, MMP-9, and MMP-13, and TIMP-1 and TIMP-2, via
AP-1 and NF-κB activation (Siwik and Colucci, 2004). Again, the
myocardial matrix also elicits TLRs and IL-1 signaling, which
in turn stimulates NF-κB. The renin–angiotensin–aldosterone
system and members of the TGF-β family play also a pivotal role
in activation of myofibroblasts (Siwik et al., 2000). Formation
of a mature cross-linked scar is associated with clearance of
fibroblasts following inhibitory signals to restrain the fibrotic
response (Shinde and Frangogiannis, 2014). However, excessive
fibrosis has been linked to increased incidence of arrhythmia and
other AMI-related pathologies (Xie et al., 2004). In this sense,
significant upregulation of IL-1 can extend to non-infarcted
areas and promote a second phase of elevated levels of cytokines,
leading to interstitial fibrosis in the non-infarcted myocardium,
and enhancing cardiac dysfunction (Shinde and Frangogiannis,
2014).
Blockade of IL-1β in Experimental HF
Several reports have demonstrated the benefit of blocking IL-1β
in experimental models of HF. Early inhibition of IL-1β signaling
is more likely to inhibit the inflammatory cascade, whereas late
inhibition may predominantly abrogate the direct actions of
IL-1β on fibroblasts (Bujak et al., 2008). In rodents, by using
genetically engineered antibody to IL-1β, cardiac enlargement
and dysfunction following AMI were reduced without affecting
the infarct size (Abbate et al., 2010). By administration of a
recombinant IL-1Ra in T1DM-induced diabetic cardiomyopathy,
the IRAK2/CHOP-dependent apoptosis was attenuated, without
affecting fasting blood glucose concentration (Liu et al.,
2015). Interestingly, in T1DM-induced diabetic cardiomyopathy,
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administration of an anti-TNF-α monoclonal antibody lessen
cardiac TNF-α and IL-1β expression in correlation with cardiac
collagen-I and -III content, and improvement of left-ventricle
function (Westermann et al., 2007).
Other strategies to control IL-1β activity in the context
of cardiomyopathy address the kallikrein–kinin system and
the NLRP3/caspase-1/TLR pathway. Transgenic activation
of kallikrein-1 ameliorated intramyocardial inflammation
through reduction of adhesion molecules, IL-1β and TNF-α,
and leukocyte infiltration, as well as endothelium dysfunction
and oxidative stress in T1DM-induced diabetic cardiomyopathy
(Tschöpe et al., 2005). Moreover, NLRP3-deficient mice
subjected to I/R exhibited a marked improvement of cardiac
function and reduction of hypoxic damage (Sandanger et al.,
2013). NLRP3 gene silencing ameliorated pyroptosis and
ROS release under high glucose in cardiomyocytes. ROS
inhibition decreased also NF-κB and mature IL-1β (Luo
et al., 2014a). Finally, NLRP3 and high-mobility group box-1
(HMGB1) knockdowns reduced cardiac hypertrophy and
fibrosis, and restored cardiac function (Fuentes-Antras et al.,
2014). Ablation of TLR4 successfully reverted architectural
aberrations and restored cardiac dysfunction in T1DM mice.
Thus, the role of HMGB1 as TLR4 ligand and upstream inducer
of NF-κB and NLRP3 may shape a key pathogenic axis in
diabetic cardiomyopathy, suggesting their potential as novel
anti-inflammatory approaches. In this context, other ligands for
TLR (TLR2 and TLR4) such as biglycan could also play a key role
in amplifying fibrotic responses after cardiac injury (Beetz et al.,
2016).
In this regard, statins as rosuvastatin have also exhibited
beneficial proprieties against diabetic cardiomyopathy
through inhibition of NLRP3 inflammasome and mature
IL-1β, via suppression of the MAPKs activation (Luo et al.,
2014b). Similar effects for pravastatin were observed also
in obese T2DM rats with AMI (Li et al., 2006). Moreover,
administration of the PDE-5 inhibitor tadalafil reduced
circulating IL-1β and TNF-α, and associated chemokines
RANTES, MIP-1β and MCP-1, after I/R induction in T2DM
mice. In parallel, tadalafil upregulated the anti-inflammatory
cytokine IL-10 and improved fasting glucose, whereas
decreased infarct size (Varma et al., 2012). In addition,
a glucocorticoid (methylprednisolone) treatment reduced
expression of TLR4/NF-κB signaling and IL-1β, IL-6, TNF-α,
and ICAM-1 on T1DM-induced diabetic cardiomyopathy
with I/R injury (Hu et al., 2011). More importantly, the
antiapoptotic property of anakinra has been demonstrated
in models of I/R injury and AMI. This action was due to a
decreased expression of pro-apoptotic mediators Bax, Bak,
and caspase-1 and -3, which promote a reduction of infarct
size and favorable ventricular remodeling (Abbate et al.,
2008). Also, in T1DM mice, released IL-1β from cardiac
macrophages stimulated with TLR2 and NLRP3 agonists,
induced a decrease in potassium current and an increase in
calcium sparks in cardiomyocytes, and subsequent cardiac
arrhythmia. Interestingly, inhibition of IL-1β signaling by either
anakinra or NLRP3 inhibitor (MCC-950) reduced these effects
(Monnerat et al., 2016).
CLINICAL TRIALS ASSESSING IL-1β
INHIBITION AND CARDIOVASCULAR
COMPLICATIONS IN PATIENTS WITH DM
Although pharmacological inhibitors of the IL-1 pathway were
first developed to control classical autoinflammatory diseases
such as rheumatoid arthritis, the increasing evidence about a key
role for this pathway in the pathophysiology of T1DM and T2DM
(see reviews by Dinarello, 2014; Ballak et al., 2015; Herder et al.,
2015; Pollack et al., 2016) provided a rationale for assessing their
therapeutic value in the context of DM. Moreover, a growing
bulk of pre-clinical data highlight the potential relevance of
IL-1β in the development of atherosclerosis and cardiovascular
dysfunction. Despite this, the number of studies conducted in
humans to assess the benefit of IL-1β inhibition on cardiovascular
outcomes in the context of DM still remains very limited
today.
Interestingly, the success of the first clinical trial reported
using a IL blocker, i.e., anakinra, in T2DM (Larsen et al.,
2007; ClinicalTrials.gov identifier: NCT00303394) reinforced the
proposal that the pharmacological control of the imbalance
of the IL-1:IL-1Ra ratio could be a relevant approach for the
treatment of this metabolic autoinflammatory disease. In such
study, 70 adult patients were treated with a 100 mg daily
dose during 13 weeks. An improvement of several markers
of glucose metabolism, such as reduction in HbA1c and an
increased C-peptide secretion were obtained, together with the
reduction of systemic inflammatory markers, such as CRP and
IL-6 levels (Larsen et al., 2007). Moreover, a 39-week follow-
up of the same study after treatment withdrawal, showed not
only a maintained reduction in inflammatory markers but also
a persistent improvement in β-cell function, as expressed by the
lower proinsulin/insulin ratio in the formerly anakinra-treated
patients as compared with those in the placebo group (Larsen
et al., 2009). However, this study did not assess any cardiovascular
outcome in the patients enrolled.
Cardiovascular Outcomes
Although the results obtained with anakinra were encouraging,
still there are characteristics that make the drug unsuitable
for long-term treatment of T2DM, such as a short half-life
(anakinra should be administered on a daily basis to maintain
adequate suppression of IL-1β) or injection-site reactions, in
addition to being an expensive option. It is also worth to
note that an anti-IL-1 strategy that saves IL-1α activity could
offer safety benefits. In fact, genome-wide association studies
recently suggested that long-term dual IL-1α/β inhibition could
increase cardiovascular risk mediated, at least in part, through an
increase in proatherogenic lipid concentrations (The Interleukin
1 Genetics Consortium, 2015). Therefore, reducing specifically
IL-1β activity with longer-lasting agents would provide a
therapeutic improvement in terms of sustained inhibition of
IL-1β. In this context, the monoclonal antibody canakinumab
achieves IL-1β inhibition, while preserving IL-1α activity. Also,
the significantly longer half-life of canakinumab (Chakraborty
et al., 2012) makes the drug more suitable for assessing outcomes
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that may require longer treatment times, such as cardiovascular
ones.
In fact, canakinumab is currently being tested in the
Canakinumab Anti-inflammatory Thrombosis Outcomes Study
(CANTOS), which is the largest trial in progress for any
anti-cytokine drug (ClinicalTrials.gov identifier: NCT01327846).
The objective is to test whether canakinumab will reduce
cardiovascular events in high-risk patients with T2DM who have
high CRP levels (hsCRP > 2 mg/L) despite receiving optimal
statin therapy. The trial is examining 17,200 individuals using
three doses of the antibody in a placebo-controlled, randomized
design in 146 centers. Although the primary outcome is based on
the hypothesis that blocking IL-1β activity in these patients may
also reduce the incidence in myocardial infarction and stroke,
secondary end points include prevention and improvement of
diabetes. CANTOS is an event driven trial due to be completed in
2017, when approximately 1400 cases of myocardial infarction,
stroke, or cardiovascular death will have accrued (Ridker et al.,
2011).
A preliminary proof-of-concept study has been already
executed within the CANTOS trial; thus, 556 well-controlled
type 2 diabetic subjects (baseline HbA1c of 7.4%) with high
cardiovascular risk have been randomly allocated to receive
monthly subcutaneous canakinumab at doses of 5, 15, 50, or
150 mg or placebo and followed over 4 months. Together
with an important dose-dependent reduction in inflammatory
markers (CRP and IL-6), there was a modest non-significant
improvement in glucose control parameters (HbA1c, glycemia,
and insulinemia), while lipoprotein levels were unchanged
(Ridker et al., 2012). In terms of cardiovascular outcomes, there
is great expectation for the results of the trial. If positive,
CANTOS would reinforce the inflammatory hypothesis of
atherothrombosis and support a cytokine-based therapy for the
secondary prevention of cardiovascular disease in T2DM.
Apart from the expected results from CANTOS, there are
very few studies available on vascular outcomes in patients
with DM and most of them show no clear cardiovascular
improvement upon IL-1β blockade. A smaller trial enrolled
189 patients with atherosclerosis in the carotid artery and/or
the aorta and either T2DM or impaired glucose tolerance
(ClinicalTrials.gov identifier: NCT00995930). The subcutaneous
administration of canakinumab (150 mg) monthly for 12 months
did not significantly affect vascular structure in terms of
carotid intima thickness, or vascular function in terms of aortic
distensibility measured by pulsed wave velocity (Choudhury
et al., 2016). Canakinumab showed an anti-inflammatory
effect by reducing the circulating levels of IL-6 and hs-
CRP, but had no effect on metabolic indicators, like fasting
glucose, HbA1c, or insulin sensitivity (Choudhury et al., 2016).
Although no cardiovascular benefit was found, the results
were not considered conclusive due to some limitations,
including the short duration of the study to assess structural
changes. Also, the lack of stratification of the patients enrolled
based on their initial inflammatory status did not permit to
identify those patients that would potentially benefit more
from IL-1β inhibition. Finally, the dose administrated was
sufficient to lower inflammatory markers but perhaps was not
high enough to generate a maximal effect on atherosclerotic
lesions.
Another prospective non-controlled pilot study was
performed with only six patients with proliferative diabetic
retinopathy, secondary to T1DM or T2DM, and receiving
subcutaneous canakinumab (150 mg) every 8 weeks
(ClinicalTrials.gov identifier: NCT01589029). No regression
of retinal neovascularization was reported after 24 weeks of
follow-up, although a positive effect on macular edema was
observed (Stahel et al., 2016). Again, the dose of canakinumab
may have been insufficient, with higher doses of 300 mg every
4 weeks being currently approved for uses such as systemic
juvenile idiopathic arthritis.
A possible limitation for these studies, in addition to sample
size or dosage, can be that the patients enrolled already exhibited
advanced stage cardiovascular disease. Thus, parallel studies
performed in diabetic patients without evidence of advanced
vascular lesions would help shedding light on the capacity of
canakinumab or other IL-1β blocking drugs to prevent or retard
the onset of atherosclerosis or other vascular alterations in the
context of DM.
Safety
Canakinumab was safe and well-tolerated in the above-
mentioned cardiovascular trials, with no significant differences in
adverse effects between treated and control groups (Choudhury
et al., 2016; Stahel et al., 2016). The upcoming results of CANTOS
will help shedding more light on the tolerability of long-term
treatments with canakinumab.
In the context of T2DM, other studies not specifically designed
to assess cardiovascular outcomes, have already provided
information on the tolerability of canakinumab. A recent study
pooled the data from trials that used different doses of the drug
(Howard et al., 2014). These trials enrolled a total of 1026 patients
with different routes of administration, treatment regimes and
follow-up time (ClinicalTrials.gov identifiers: NCT00900146 and
NCT00605475; Ridker et al., 2012; Rissanen et al., 2012; Hensen
et al., 2013; Noe et al., 2014). The global analysis of the three
trials demonstrated that canakinumab was safe and well tolerated
over a treatment period up to 1.4 years at the four pooled
doses evaluated, which was in agreement with safety findings
reported in the individual studies (Howard et al., 2014). No
significant differences were evidenced in terms of adverse effects,
discontinuations or deaths between treatment and placebo
(Howard et al., 2014). Overall, canakinumab seems safe and well
tolerated by patients with T2DM. However, additional trials with
longer follow-up times are still needed to assess whether the drug
will be suitable for longer-term treatment of a chronic conditions
such as T2DM.
CONCLUDING REMARKS
The growing body of evidence pointing at IL-1β as a key player
in the development of DM and its cardiovascular complications
provides nowadays a solid rationale for IL-1 blockade as
a potential pharmacological approach to treat the disease.
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While IL-1 inhibition seems to be rather promising in controlling
the pro-inflammatory status and even in ameliorating glucose
homeostasis in the context of DM, evidence is lacking on its
potential benefits on the cardiovascular complications of the
disease.
Most of the positive results obtained to date in terms
of cardiovascular improvement arise from pre-clinical
data mostly performed through ex vivo or in vitro
approaches. Clearly, further experimental studies using in vivo
experimental models are required to better understand
the pharmacological effects and mechanisms of actions
of IL-1β blockers on the cardiovascular system. This
will help identifying which conditions may benefit more
from IL-1β blockade and predicting potential adverse
effects.
At present, the knowledge derived from studies in humans
remains very limited. Despite promising results, additional
studies need to be performed to better assess the tolerability,
and, importantly, the long-term safety of the drugs that may
achieve long-lasting IL-1β blockade. In terms of clinical efficacy,
more trials are needed with an accurate patient selection based
on the stage and complications of the disease. Studies such
as the CANTOS trial are soon expected to shed light on the
impact of long-lasting IL-1β inhibitors on the cardiovascular
complications of DM. This and forthcoming studies, that may
include novel pharmacological approaches such as therapeutic
vaccination, will allow answering whether or not IL-1β is indeed a
valuable therapeutic target to reduce the burden of cardiovascular
diabetic complications.
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